[go: up one dir, main page]

ECSP13012382A - Composiciones sólidas - Google Patents

Composiciones sólidas

Info

Publication number
ECSP13012382A
ECSP13012382A ECSP13012382A ECSP13012382A EC SP13012382 A ECSP13012382 A EC SP13012382A EC SP13012382 A ECSP13012382 A EC SP13012382A EC SP13012382 A ECSP13012382 A EC SP13012382A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
solid compositions
compound
acceptable salt
amorphous
Prior art date
Application number
Other languages
English (en)
Inventor
Bernd Liepold
Rudolf Schroeder
Justin Lafountaine
Tina Jung
Nancy E Sever
Yi Gao
Jianwei Wu
Bryan K Erickson
Simon Kullmann
Mirko Pauli
Renato Koening
Madlen Thiel
Gerd Woehrle
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44317041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/813,301 external-priority patent/US8691938B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP13012382A publication Critical patent/ECSP13012382A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Composiciones sólidas que comprenden un compuesto IA, IB, IC o ID, o una sal farmacéuticamente aceptable de éste, en una forma amorfa. En una forma de realización, el compuesto IA, IB, IC o ID, o una sal farmacéuticamente aceptable de éste, se formula en una dispersión sólida amorfa que comprende un polímero hidrofílico farmacéuticamente aceptable, y preferiblemente un agente tensioactivo farmacéuticamente aceptable.
ECSP13012382 2010-06-10 2013-01-10 Composiciones sólidas ECSP13012382A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35355310P 2010-06-10 2010-06-10
US12/813,301 US8691938B2 (en) 2009-06-11 2010-06-10 Anti-viral compounds

Publications (1)

Publication Number Publication Date
ECSP13012382A true ECSP13012382A (es) 2013-03-28

Family

ID=44317041

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012382 ECSP13012382A (es) 2010-06-10 2013-01-10 Composiciones sólidas

Country Status (41)

Country Link
US (2) US8686026B2 (es)
EP (3) EP2954892B1 (es)
JP (1) JP5814356B2 (es)
KR (3) KR101481395B1 (es)
CN (1) CN103209686B (es)
AR (1) AR083240A1 (es)
AU (1) AU2011264823B2 (es)
BR (2) BR112012031500A8 (es)
CA (1) CA2802180C (es)
CL (1) CL2012003470A1 (es)
CO (1) CO6660490A2 (es)
CR (1) CR20120650A (es)
CY (2) CY1116748T1 (es)
DK (2) DK2579854T4 (es)
DO (1) DOP2012000307A (es)
EA (1) EA024538B1 (es)
EC (1) ECSP13012382A (es)
ES (2) ES2546767T5 (es)
GT (1) GT201200332A (es)
HR (2) HRP20150926T4 (es)
HU (2) HUE039719T2 (es)
IL (1) IL223535A (es)
LT (1) LT2954892T (es)
ME (1) ME02201B (es)
MX (1) MX2012014384A (es)
MY (1) MY164607A (es)
NZ (1) NZ605440A (es)
PE (1) PE20131036A1 (es)
PH (1) PH12012502442A1 (es)
PL (2) PL2954892T3 (es)
PT (2) PT2954892T (es)
RS (2) RS54282B2 (es)
SG (1) SG186251A1 (es)
SI (2) SI2579854T2 (es)
SM (2) SMT201800532T1 (es)
TR (1) TR201815161T4 (es)
TW (1) TWI487700B (es)
UA (1) UA105434C2 (es)
UY (1) UY33446A (es)
WO (1) WO2011156578A1 (es)
ZA (1) ZA201300112B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
EP2853531A3 (en) 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102863428B (zh) 2011-07-09 2014-12-24 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的螺环化合物
US9012634B2 (en) 2011-08-10 2015-04-21 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2015100283B4 (en) * 2011-10-21 2015-06-18 Abbvie Ireland Unlimited Company Methods for treating HCV
SG2014011647A (en) * 2011-10-21 2014-08-28 Abbvie Inc Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
US20130172240A1 (en) * 2011-12-28 2013-07-04 Abbvie Inc. Methods for treating hcv
CA2857339C (en) * 2011-12-29 2015-11-17 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2015516421A (ja) * 2012-05-07 2015-06-11 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの経口固形製剤
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
WO2014082379A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
HUE047777T2 (hu) * 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EA032322B1 (ru) 2013-03-15 2019-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
MX2015017953A (es) 2013-07-02 2016-10-28 Abbvie Inc Metodos para tratar el virus de hepatitis c.
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US20160296463A1 (en) * 2013-11-11 2016-10-13 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods thereof
JP6232262B2 (ja) * 2013-11-13 2017-11-15 アクアス株式会社 徐放性を有する固形水処理剤、およびその製造方法
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR20220136460A (ko) * 2014-02-05 2022-10-07 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
WO2015171162A1 (en) * 2014-05-09 2015-11-12 Abbvie Inc. Anti-viral compound
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016010771A1 (en) * 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
CN107920996A (zh) * 2015-06-26 2018-04-17 艾伯维公司 用于治疗hcv的固体药物组合物
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017004733A1 (zh) * 2015-07-03 2017-01-12 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
HK1255203A1 (zh) * 2015-07-17 2019-08-09 Abbvie Inc. 用於治疗hcv的固体药物组合物
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017038925A1 (ja) * 2015-09-03 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
TW201718608A (zh) * 2015-11-23 2017-06-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd 用於抗ｃ型肝炎病毒感染的含矽化合物
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP7246386B2 (ja) * 2017-07-20 2023-03-27 エイエムアールアイ エスエスシーアイ， リミテッド ライアビリティ カンパニー エピガロカテキンガレートの非晶質分散体
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
KR102286706B1 (ko) 2020-09-29 2021-08-06 솔브레인 주식회사 바나듐 전해액 제조방법
KR102286707B1 (ko) 2020-10-30 2021-08-06 솔브레인 주식회사 바나듐 전해액 제조방법 및 제조장치
KR102286709B1 (ko) 2020-11-03 2021-08-06 솔브레인 주식회사 바나듐 전해액 제조장치
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US12350259B2 (en) 2021-09-27 2025-07-08 Allergan Pharmaceuticals International Limited Methods of treating migraine
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US353553A (en) 1886-11-30 Du bois f
DE75755C (de) 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
US813301A (en) 1903-09-09 1906-02-20 Frank S Hyde Steam-engine.
EP0701446A4 (en) 1993-05-24 1997-04-23 Smithkline Beecham Corp HEMOREGULATORS PEPTIDES
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6235493B1 (en) 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
CN1721411A (zh) 1998-05-22 2006-01-18 阿文尼尔药品公司 作为IgE调节剂的苯并咪唑衍生物
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ES2245955T3 (es) 1999-12-21 2006-02-01 Sugen, Inc. 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
CN1441806A (zh) 2000-04-05 2003-09-10 先灵公司 包含n－环p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7065453B1 (en) 2000-06-15 2006-06-20 Accelrys Software, Inc. Molecular docking technique for screening of combinatorial libraries
ES2281434T3 (es) 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US6388093B1 (en) 2001-01-05 2002-05-14 Sun Chemical Corporation Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles
BR0210357A (pt) 2001-06-11 2004-06-29 Shire Biochem Inc Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
RU2286343C2 (ru) 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
JP3925265B2 (ja) 2002-03-25 2007-06-06 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及びそれを用いた表示装置
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
PL374190A1 (en) 2002-06-14 2005-10-03 Merck & Co, Inc. Mitotic kinesin inhibitors
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20060003942A1 (en) 2003-10-27 2006-01-05 Roger Tung Combinations for HCV treatment
BRPI0401908A (pt) 2004-06-04 2006-01-17 Univ Rio De Janeiro Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
BRPI0513811A (pt) 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
WO2006020951A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
AU2006211159A1 (en) 2005-02-01 2006-08-10 Wyeth Amino-pyridines as inhibitors of beta-secretase
WO2006088711A1 (en) 2005-02-14 2006-08-24 Wyeth AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
EP1907398A1 (en) 2005-07-15 2008-04-09 AstraZeneca AB Therapeutic agents
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
CA2633541A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
DE602006015861D1 (de) 2005-12-21 2010-09-09 Abbott Lab Antivirale verbindungen
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2007146758A2 (en) 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
MX2008015717A (es) 2006-06-16 2008-12-19 Syngenta Participations Ag Derivados de etenil carboxamida utiles como microbiocidas.
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
WO2008074450A2 (en) 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
CA2684169C (en) 2007-04-12 2012-06-19 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
WO2009020534A2 (en) 2007-08-03 2009-02-12 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
PL2250163T3 (pl) 2008-02-12 2012-10-31 Bristol Myers Squibb Co Inhibitory wirusa zapalenia wątroby typu C
CA2715400A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis c virus inhibitors
EA018088B1 (ru) 2008-02-13 2013-05-30 Бристол-Маерс Сквибб Компани Имидазолилбифенильные имидазолы в качестве ингибиторов вируса гепатита с
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI583405B (zh) 2008-02-28 2017-05-21 艾伯維有限公司 錠劑及其製備
JP5818681B2 (ja) 2008-04-01 2015-11-18 ノボ・ノルデイスク・エー／エス インスリンアルブミンコンジュゲート
US20110117081A1 (en) 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009143361A1 (en) 2008-05-22 2009-11-26 Smithkline Beecham Corporation Amido anti-viral compounds
EP2310402A1 (en) 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
EP2540350B1 (en) 2008-07-22 2014-05-21 Merck Sharp & Dohme Corp. Combinations of a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor with other hcv agents
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010059858A1 (en) 2008-11-19 2010-05-27 Duke University Manassantin compounds and methods of making and using same
JP2010126571A (ja) 2008-11-26 2010-06-10 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CA2746004C (en) 2008-12-03 2017-06-06 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
UY32462A (es) 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
JP5628841B2 (ja) 2009-02-27 2014-11-19 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビター
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MA33209B1 (fr) 2009-03-27 2012-04-02 Merck Sharp & Dohme Inhibiteurs de la replication du virus de l'hepatite c
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102388046A (zh) 2009-04-08 2012-03-21 巴斯夫欧洲公司 吡咯并吡咯衍生物、其制备及作为半导体的用途
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
CN102414199B (zh) 2009-04-24 2014-03-05 泰博特克药品公司 二芳基醚
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
KR101727876B1 (ko) 2009-05-13 2017-04-17 길리애드 파마셋 엘엘씨 항바이러스 화합물
JP2012528194A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
IN2012DN00999A (es) 2009-07-16 2015-04-10 Vertex Pharma
EP2462135A1 (en) 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
CA2772484A1 (en) 2009-09-03 2011-03-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives
KR20120076343A (ko) 2009-09-04 2012-07-09 글락소스미스클라인 엘엘씨 화합물
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CA2781140C (en) 2009-12-04 2017-10-24 National Health Research Institutes Proline derivatives for use to treat hepatitis c infection
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
EP2515902A1 (en) 2009-12-24 2012-10-31 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
MA34013B1 (fr) 2010-01-25 2013-02-01 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
JP2013518062A (ja) 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
EA201201235A1 (ru) 2010-03-04 2013-04-30 Энанта Фармасьютиклз, Инк. Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP2013522377A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011150243A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20130310427A1 (en) 2010-06-09 2013-11-21 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
CA2812699A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
US20130280214A1 (en) 2010-09-29 2013-10-24 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
MX2013003631A (es) 2010-09-29 2013-10-01 Merck Sharp & Dohme Derivados de indol tetraciclicos y sus métodos para el tratamiento de enfermedades virales.
CN103189371B (zh) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 丙型肝炎病毒抑制剂
JP5905020B2 (ja) 2010-11-17 2016-04-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
CY1122267T1 (el) 2020-07-31
CO6660490A2 (es) 2013-04-30
ES2546767T3 (es) 2015-09-28
SI2579854T1 (sl) 2015-09-30
ZA201300112B (en) 2013-09-25
ES2546767T5 (es) 2018-07-27
PH12012502442A1 (en) 2022-03-21
CA2802180C (en) 2018-12-18
DK2579854T3 (en) 2015-10-19
US8686026B2 (en) 2014-04-01
BR112012031500A8 (pt) 2022-11-01
NZ605440A (en) 2014-05-30
EP3456318A1 (en) 2019-03-20
KR101481395B1 (ko) 2015-01-13
EP2579854A1 (en) 2013-04-17
HRP20150926T1 (xx) 2015-10-09
CY1116748T1 (el) 2017-03-15
CN103209686A (zh) 2013-07-17
KR20150008151A (ko) 2015-01-21
EP2954892B1 (en) 2018-07-18
HUE025758T2 (en) 2016-04-28
SMT201800532T1 (it) 2018-11-09
BR212012031500U2 (pt) 2015-11-17
HRP20150926T4 (hr) 2018-11-30
TR201815161T4 (tr) 2018-11-21
EP2579854B2 (en) 2018-07-04
PL2579854T5 (pl) 2018-12-31
EP2954892A1 (en) 2015-12-16
WO2011156578A1 (en) 2011-12-15
DK2954892T3 (en) 2018-10-29
RS54282B2 (sr) 2018-08-31
TWI487700B (zh) 2015-06-11
SMT201500263B (it) 2016-01-08
PT2954892T (pt) 2018-11-09
PT2579854E (pt) 2015-10-16
TW201204713A (en) 2012-02-01
EP2579854B1 (en) 2015-07-15
DK2579854T4 (en) 2018-10-22
EA024538B1 (ru) 2016-09-30
AU2011264823A1 (en) 2013-01-24
CN103209686B (zh) 2015-06-17
UY33446A (es) 2012-01-31
KR20180023014A (ko) 2018-03-06
IL223535A (en) 2017-02-28
EA201291394A1 (ru) 2013-05-30
CR20120650A (es) 2013-05-16
SG186251A1 (en) 2013-01-30
LT2954892T (lt) 2018-12-10
HK1184068A1 (zh) 2014-01-17
JP2013528225A (ja) 2013-07-08
US20140171481A1 (en) 2014-06-19
SI2954892T1 (sl) 2019-01-31
AR083240A1 (es) 2013-02-13
UA105434C2 (uk) 2014-05-12
MY164607A (en) 2018-01-30
ES2691625T3 (es) 2018-11-28
PE20131036A1 (es) 2013-10-20
SI2579854T2 (sl) 2018-10-30
PL2579854T3 (pl) 2015-12-31
CA2802180A1 (en) 2011-12-15
KR102059386B1 (ko) 2019-12-26
HUE039719T2 (hu) 2019-01-28
JP5814356B2 (ja) 2015-11-17
GT201200332A (es) 2014-11-06
RS54282B1 (sr) 2016-02-29
BR112012031500A2 (es) 2015-11-17
PL2954892T3 (pl) 2019-02-28
KR20130053440A (ko) 2013-05-23
MX2012014384A (es) 2013-05-01
US20120258909A1 (en) 2012-10-11
RS57982B1 (sr) 2019-01-31
HRP20181658T1 (hr) 2019-01-11
DOP2012000307A (es) 2013-01-31
AU2011264823B2 (en) 2014-03-13
ME02201B (me) 2016-02-20
CL2012003470A1 (es) 2013-02-15

Similar Documents

Publication Publication Date Title
ECSP13012382A (es) Composiciones sólidas
CO6640208A2 (es) Composiciones solidas
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
CR20130224A (es) Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
EP2585999A4 (en) ACCELERATION OF SOCIAL INTERACTIONS
LT2811998T (lt) Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sistemiškai veikiančius aktyviuosius agentus, būdai ir jų panaudojimas
AP2014008017A0 (en) Parasiticidal compositions comprising multiple active agents, methods and uses thereof
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
EP2318395A4 (en) IAP INHIBITORS
BR112012001756A2 (pt) "dispositivo de transmissão anti-queda para porta de manuseio com cortina flexível".,
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
CO6852097A2 (es) Agentes de coalescencia amigables con el medio ambiente
GB201021864D0 (en) Organic compounds
BRPI1011051A2 (pt) "desinfetante para as mãos"
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
FR2967883B1 (fr) Suceur d'aspirateur
ITAN20120150A1 (it) Servomeccanismo per l'apertura di una serratura.
FR2958143B1 (fr) Suceur d'aspirateur
AR083796A1 (es) Composicion sinergistica antimicrobiana de 1,2-benzisotiazolin-3-ona y tris(hidroximetil)nitrometano
CR20120632A (es) Composiciones sòlidas
BRPI1014211A2 (pt) "composição."
RU2008123590A (ru) Средство с мембраностабилизирующим эффектом
TH139648A (th) องค์ประกอบชนิดแข็งซึ่งประกอบรวมด้วยสารประกอบ IA, Ib, Ic หรือ Id
UA52370U (ru) Применение глюкозамина гидрохлорида в качестве средства фригопротекторного действия
UA21324S (uk) Атракціон «евеліна»